The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form.
Related Articles
Senza categoria
The neglected magic bullet
Senza categoria
Health rationing in Europe: can cancer get a fair hearing?
News